Association between chronic sodium-glucose cotransporter 2 inhibitors use and right ventricular function in hemodynamically stable patients with acute pulmonary embolism

Background Acute pulmonary embolism (PE) is a common cardiovascular disorder associated with substantial morbidity and mortality, with prognosis largely determined by the extent of right ventricular (RV) involvement. Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve outcomes in patients with heart failure (HF) and exert favorable effects on left ventricular (LV) remodeling; however, their effects on RV function in acute PE remain largely unexplored. We hypothesized that chronic treatment with SGLT2 inhibitors would be associated with a lower incidence of clinical congestion and a more favorable clinical course in patients with acute PE. Methods We retrospectively compared 30 patients receiving chronic SGLT2 inhibitor therapy with 90 controls following 1:3 matching for multiple variables, including age, sex, comorbidities, and background medical therapy. Echocardiographic and clinical outcomes were compared between the groups, including tricuspid annular plane systolic excursion (TAPSE), systolic pulmonary artery pressure (SPAP), and clinical congestion. Results Patients receiving SGLT2 inhibitors had higher TAPSE values (19.4 ± 2.7 vs. 17.3 ± 5, 95% Confidence interval (CI) 0.7–3.5, p = 0.004), fewer signs of clinical congestion [6.7% vs. 25.6%, Odds ratio (OR) 0.21, 95% CI 0.05–0.94, p = 0.03], lower troponin, [14.5 (5.3–51), vs. 64.5 (20–177), 95% CI (33–108), p < 0.001], and lower N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, [158 (96–443) vs. 1000 (333–3433), 95% CI (467–1153) pg/mL, p < 0.001]. No significant between-group difference was observed in 1-year readmissions due to dyspnea or clinical congestion [OR 0.34, 95% CI (0.1–1.2), p = 0.13]. Conclusions Among hemodynamically stable patients with acute PE, chronic SGLT2 inhibitor therapy was associated with more favorable RV function during the index event; however, this association did not translate into improved long-term clinical outcomes. These findings warrant confirmation in prospective studies.

Authors

Institutions

Publication Details

Journal
Frontiers in Cardiovascular Medicine
Published
2026-10-26
DOI
https://doi.org/10.3389/fcvm.2026.1975531
Primary Topic
Venous Thromboembolism Diagnosis and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Association between chronic sodium-glucose cotransporter 2 inhibitors use and right ventricular function in hemodynamically stable patients with acute pulmonary embolism

Robert Dragu, Gassan Moady, Shaul Atar, Lihi Levi-Gofman et al.
Frontiers in Cardiovascular Medicine
Venous Thromboembolism Diagnosis and Management
article

Association between chronic sodium-glucose cotransporter 2 inhibitors use and right ventricular function in hemodynamically stable patients with acute pulmonary embolism

Robert Dragu, Gassan Moady, Shaul Atar, Lihi Levi-Gofman, Shir Maman
article en

Abstract

Background Acute pulmonary embolism (PE) is a common cardiovascular disorder associated with substantial morbidity and mortality, with prognosis largely determined by the extent of right ventricular (RV) involvement. Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve outcomes in patients with heart failure (HF) and exert favorable effects on left ventricular (LV) remodeling; however, their effects on RV function in acute PE remain largely unexplored. We hypothesized that chronic treatment with SGLT2 inhibitors would be associated with a lower incidence of clinical congestion and a more favorable clinical course in patients with acute PE. Methods We retrospectively compared 30 patients receiving chronic SGLT2 inhibitor therapy with 90 controls following 1:3 matching for multiple variables, including age, sex, comorbidities, and background medical therapy. Echocardiographic and clinical outcomes were compared between the groups, including tricuspid annular plane systolic excursion (TAPSE), systolic pulmonary artery pressure (SPAP), and clinical congestion. Results Patients receiving SGLT2 inhibitors had higher TAPSE values (19.4 ± 2.7 vs. 17.3 ± 5, 95% Confidence interval (CI) 0.7–3.5, p = 0.004), fewer signs of clinical congestion [6.7% vs. 25.6%, Odds ratio (OR) 0.21, 95% CI 0.05–0.94, p = 0.03], lower troponin, [14.5 (5.3–51), vs. 64.5 (20–177), 95% CI (33–108), p < 0.001], and lower N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, [158 (96–443) vs. 1000 (333–3433), 95% CI (467–1153) pg/mL, p < 0.001]. No significant between-group difference was observed in 1-year readmissions due to dyspnea or clinical congestion [OR 0.34, 95% CI (0.1–1.2), p = 0.13]. Conclusions Among hemodynamically stable patients with acute PE, chronic SGLT2 inhibitor therapy was associated with more favorable RV function during the index event; however, this association did not translate into improved long-term clinical outcomes. These findings warrant confirmation in prospective studies.

Frontiers in Cardiovascular MedicineVol. 13
Bar-Ilan University (IL), Western Galilee Hospital (IL), Istituto Nazionale di Fisica Nucleare, Galileo Galilei Institute for Theoretical Physics (IT)
Openalex Percentile: Top 10%
Venous Thromboembolism Diagnosis and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon